Free Trial

BioStem Technologies (OTCMKTS:BSEM) Stock Price Up 10% - What's Next?

BioStem Technologies logo with Medical background

BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) shares shot up 10% during trading on Thursday . The company traded as high as $11.50 and last traded at $11.50. 41,418 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 48,415 shares. The stock had previously closed at $10.45.

BioStem Technologies Stock Down 2.2%

The company has a market capitalization of $188.33 million, a price-to-earnings ratio of 7.65 and a beta of -0.27. The business has a 50-day moving average price of $12.56 and a 200-day moving average price of $12.84.

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $1.25 by ($1.08). The firm had revenue of $72.53 million during the quarter, compared to analyst estimates of $101.20 million. As a group, sell-side analysts predict that BioStem Technologies, Inc. will post 1.41 EPS for the current year.

BioStem Technologies Company Profile

(Get Free Report)

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.

Featured Articles

Should You Invest $1,000 in BioStem Technologies Right Now?

Before you consider BioStem Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.

While BioStem Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines